September
12

The state of the HIV market in low- and middle-income countries

Published September 12th, 2018

By: Shaun McGovern, HIV Regional Manager for Southern Africa; Zack Panos, HIV Market Intelligence Associate; Manasa Reddy, HIV Market Intelligence Associate; and Vineet Prabhu, HIV Market Intelligence Associate Director

A clear understanding of the complex, ever-changing antiretroviral (ARV) and diagnostic markets in low- and middle-income countries is critical for all stakeholders in the HIV space. To address this need, CHAI publishes an annual HIV market report for public consumption based on aggregated market intelligence from our programmatic work in over 30 countries. We are pleased to release the 9th issue of this report, HIV Market Report: The State of the HIV Treatment, Testing, and Prevention Markets in Low- and Middle-Income Countries (2017 – 2022).



Key updates from the past twelve months highlighted in this year’s HIV Market Report include:

     • New treatment guidelines, released by the World Health Organization in July 2018, recommend the use of      dolutegravir-containing regimens for all people living with HIV older than 4 weeks old, in both first- and second-      line therapy, with special considerations for women of childbearing potential

     • Updates to the early infant diagnosis testing cascade, including recommendations to reduce the number of false      positives, ensuring children are tested through the exposure period, and codifying the use of point-of-care      technologies for confirmatory testing

     • An updated Optimal Formulary and Limited-Use List for Pediatric ARVs outlines the best formulations for treating      pediatric HIV

     • Further reductions in the cost of treatment across lines of therapy, allowing countries to continue to scale up      their HIV programs within a tight funding climate

     • Overviews of pipeline ARV products, for both treatment and prevention, that may impact the HIV market in the      years to come

     • Updates on the HIV self-testing market, including the latest procurement forecasts, information on policies in      countries, and emerging evidence supporting rollout in low- and middle-income countries

     • A landmark pricing deal dramatically reducing the cost of and simplifying the pricing structure of virological      testing for HIV, hepatitis, and HPV

     • The development of the first-ever Essential Diagnostics List by the WHO, allowing countries to prioritize and      advocate for diagnostic tests

The CHAI HIV Access Program’s mission is to ensure rapid access to the best health products at affordable and sustainable prices for patients in resource-limited settings. CHAI supports partner governments in scaling up their HIV response by working toward high quality and cost-effective treatment, testing, and prevention for all people living with HIV/AIDS. On the supply side, CHAI aims to support a reliable and transparent marketplace for HIV drugs and diagnostics to ensure a sustainable supply of life-saving health commodities for patients.

If you have any questions about this year’s HIV Market Report or would like to learn more about the HIV market in general, please contact Vineet Prabhu at vprabhu@clintonhealthaccess.org.